Side-by-side · Research reference

SNAP-8vsSS-31

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticHUMAN-REVIEWED8/46 cited

BPhase 3HUMAN-REVIEWED9/43 cited

SNAP-8

Synthetic Octapeptide · Cosmetic Topical

TopicalRoute

8-AAPeptide length

SNAREPrimary target

Topical · Facial application · Twice daily

SS-31

Cardiolipin-binding · Mitochondrial protective

40 mgDaily doseSzeto 2014

Phase 3Evidence levelSzilagyi 2009 Szeto 2014

~3 hrHalf-life

SQ · Abdomen · Once daily

01Mechanism of Action

Parameter

SNAP-8

SS-31

Primary target

SNARE complex (SNAP-25 competitive binding site)

Cardiolipin in inner mitochondrial membraneSzeto 2014

Pathway

Acetyl octapeptide-3 → SNARE complex disruption → Reduced vesicular fusion → Decreased acetylcholine release → Muscle relaxation

Cardiolipin binding → cristae stabilisation → ETC integrity → reduced ROS + preserved ATP synthesisSzeto 2014 Szilagyi 2009

Downstream effect

Transient reduction in neuromuscular signal transmission, decreased muscle contraction amplitude, wrinkle depth reduction

Mitochondrial bioenergetic preservation; cardio-, neuro-, and reno-protective effects in animal + clinical studiesSzeto 2014

Feedback intact?

N/A — topical cosmetic, no systemic endocrine axis

—

Origin

Synthetic peptide derived from N-terminal fragment of SNAP-25 protein (synaptosomal-associated protein 25 kDa)

Synthetic tetrapeptide D-Arg-Dmt-Lys-Phe-NH₂; cell-permeable, mitochondrial-selectiveSzeto 2014

Antibody development

—

02Dosage Protocols

Parameter

SNAP-8

SS-31

Typical concentration

2–10% in cosmetic formulationsLupin 2024 Raikou 2017

Commercial products typically use 5–10%.

—

Application frequency

Twice daily (morning and evening)Lupin 2024

—

Treatment duration

20–60 days for visible effectRaikou 2017

Skin microtopography improvements measured at 20-day intervals.

—

Formulation type

Oil-in-water emulsion, serum, cream

—

Application site

Facial skin — glabellar lines, crow's feet, forehead

—

Evidence basis

RCT, in vitro skin penetration studies

Multiple Phase 3 trials (Barth, AMD, ischemia-reperfusion)Szeto 2014 Szilagyi 2009

Onset of effect

Visible reduction in wrinkle depth by day 20–28Raikou 2017

—

Standard dose

—

40 mg / day SQ (clinical trials)Szeto 2014

Anecdotal community range 5-10 mg/day. Phase 3 trials use 40 mg.

Frequency

—

Once daily

Lower / starter dose

—

5 mg / day (anecdotal)

Duration

—

Indefinite for mitochondrial disease; cycled for healthspan use

Reconstitution

—

Bacteriostatic water

Timing

—

Morning fasted preferred; pre-workout for exercise-induced mitochondrial stress

Half-life

—

~3 h plasma; tissue uptake longer

03Metabolic / Fat Loss Evidence

04Side Effects & Safety

Parameter

SNAP-8

SS-31

Cytotoxicity

Concentration-dependent antiproliferative effect observed in vitro; IC50 ~10 mg/mL (argireline, 6-AA analogue)

Commercial formulations typically use 0.05–0.1 mg/mL, well below cytotoxic threshold.

—

Skin irritation

Minimal; well-tolerated in clinical use

—

Peptide oxidation

Methionine residue susceptible to oxidation in formulation; may reduce efficacyKluczyk 2021

Formulation stability issue, not a direct adverse effect.

—

Systemic absorption

Negligible; peptide remains in stratum corneum and epidermisKraeling 2015

—

Hypersensitivity

Rare; no widespread allergic reactions reported

—

Injection site reaction

—

Erythema, mild pruritus

GI symptoms

—

Nausea (uncommon)

Headache

—

Reported in some Phase 3 trials

Cardiovascular

—

Cardio-protective in studies; no signal of harm

Long-term safety

—

Phase 3 data over 24+ months; no major safety signalsSzeto 2014

Pregnancy / OB

—

Avoid — insufficient data

Absolute Contraindications

SNAP-8

·Known hypersensitivity to acetyl octapeptide-3 or formulation excipients

SS-31

·Pregnancy / breastfeeding
·Hypersensitivity to peptide

Relative Contraindications

SNAP-8

·Active skin infections or open wounds at application site
·Neuromuscular disorders (theoretical concern, no documented cases)

SS-31

·None established

05Administration Protocol

Parameter

SNAP-8

SS-31

1. Cleansing

Wash face with gentle cleanser and pat dry. Remove makeup and surface oils to optimize peptide contact.

Add bacteriostatic water per label. Light-protected handling.

2. Application

Apply 1–2 drops or pea-sized amount of SNAP-8 serum or cream to target areas (forehead, glabellar lines, crow's feet). Gently massage until absorbed.

SQ — abdomen or thigh. Rotate sites.

3. Frequency

Twice daily — morning and evening. Allow 2–3 minutes for absorption before applying additional skincare products.

Morning fasted; pre-workout for exercise-augmented mitochondrial stress.

4. Layering

Apply before heavier creams or occlusive moisturizers. Peptides penetrate best from water-based serums on clean skin.

Lyophilised: refrigerate, light-protected. Reconstituted: refrigerate ≤30 days.

5. Storage

Store at room temperature, away from direct sunlight. Refrigeration may extend shelf life of formulations containing unstable peptides.

29–31G, 4–8 mm insulin syringe.

6. Duration

Consistent use for 20–60 days required for visible wrinkle reduction. Effects are temporary and reverse upon discontinuation.

—

06Stack Synergy

SNAP-8

— no documented stacks

SS-31

+ MOTS-c

Moderate

View MOTS-c →

SS-31 and MOTS-c address mitochondrial decline through complementary axes. SS-31 protects existing mitochondrial structure (cardiolipin binding, cristae stabilisation). MOTS-c upregulates AMPK/PGC-1α, triggering biogenesis of new mitochondria. Together they pair preservation with renewal — anecdotally favoured in healthspan and post-cardio-event recovery protocols.

SS-31: 5–10 mg SQ · daily morning
MOTS-c: 5 mg SQ · 2× per week pre-workout
Primary benefit: Mitochondrial preservation + biogenesis